诺瓦瓦克斯医药(NVAX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVAX 诺瓦瓦克斯医药

盘前交易 12-05 07:34:31 EST

6.86

+0.02

+0.29%

盘前6.86

+0.000.00%

04:15 EST

最高6.87	最低6.73	成交量208.66万
今开6.78	昨收6.84	日振幅2.05%
总市值11.15亿	流通市值9.38亿	总股本1.62亿
成交额1,422万	换手率1.53%	流通股本1.37亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVAX","market":"US","secType":"STK","nameCN":"诺瓦瓦克斯医药","latestPrice":6.86,"timestamp":1764882000000,"preClose":6.84,"halted":0,"volume":2086600,"hourTrading":{"tag":"盘前","latestPrice":6.86,"preClose":6.86,"latestTime":"04:15 EST","volume":1000,"amount":6860,"timestamp":1764926158198},"delay":0,"floatShares":136723812,"shares":162498995,"eps":2.070543,"marketStatus":"盘前交易","change":0.02,"latestTime":"12-05 07:34:31 EST","open":6.78,"high":6.87,"low":6.73,"amount":14220495.53722,"amplitude":0.020468,"askPrice":6.99,"askSize":140,"bidPrice":6.68,"bidSize":100,"shortable":3,"etf":0,"ttmEps":2.070543,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1764945000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":6.86,"preHourTrading":{"tag":"盘前","latestPrice":6.86,"preClose":6.86,"latestTime":"04:15 EST","volume":1000,"amount":6860,"timestamp":1764926158198},"postHourTrading":{"tag":"盘后","latestPrice":6.8399,"preClose":6.86,"latestTime":"19:59 EST","volume":100590,"amount":689765.5847,"timestamp":1764896387983},"volumeRatio":0.8103307893521853,"impliedVol":0.7501,"impliedVolPercentile":0.0803},"requestUrl":"/m/hq/s/NVAX","defaultTab":"news","newsList":[{"id":"1199033044","title":"美股异动 | 疫苗股下跌，Moderna跌超6%！FDA提及儿童死亡与新冠疫苗关联","url":"https://stock-news.laohu8.com/highlight/detail?id=1199033044","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199033044?lang=zh_cn&edition=full","pubTime":"2025-12-01 23:26","pubTimestamp":1764602786,"startTime":"0","endTime":"0","summary":"12月1日，部分美股疫苗股盘中下跌，$Moderna(MRNA)$跌超6%，$诺瓦瓦克斯(NVAX)$跌近4%，$BioNTech(BNTX)$跌超3%。此前$美国食品(USFD)$药物管理局备忘录提及儿童死亡与新冠疫苗的关联。","market":"us","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f5a0c542474fbfdd95db309645c9c3a7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNA","NVAX","BNTX"],"gpt_icon":0},{"id":"1111401391","title":"诺瓦瓦克斯医药 - FDA批准将Nuvaxovid授权转移至赛诺菲 - SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1111401391","media":"投资观察","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111401391?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:33","pubTimestamp":1763570005,"startTime":"0","endTime":"0","summary":"11月4日 - 诺瓦瓦克斯医药公司公告：FDA已批准将Nuvaxovid的授权转移至赛诺菲。根据SEC文件，Nuvaxovid的市场授权转移将促使赛诺菲向诺瓦瓦克斯支付2500万美元。诺瓦瓦克斯预计将在2026年第一季度收到赛诺菲的里程碑付款。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4585","BK4568","BK4139","BK4588","NVAX"],"gpt_icon":0},{"id":"2583533998","title":"股东敦促诺瓦瓦克斯医药进行战略调整，警告称或考虑发起代理权争夺战","url":"https://stock-news.laohu8.com/highlight/detail?id=2583533998","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583533998?lang=zh_cn&edition=full","pubTime":"2025-11-13 09:56","pubTimestamp":1762998969,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4588","BK4585","BK4547","NVAX","BK4568","BK4139"],"gpt_icon":0},{"id":"1111971531","title":"Shah Capital：“诺瓦瓦克斯医药的股东更应在一家更大且更有能力的制药公司旗下获得服务”","url":"https://stock-news.laohu8.com/highlight/detail?id=1111971531","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111971531?lang=zh_cn&edition=full","pubTime":"2025-11-13 05:20","pubTimestamp":1762982419,"startTime":"0","endTime":"0","summary":"Shah Capital：“诺瓦瓦克斯医药的股东更应在一家更大且更有能力的制药公司旗下获得服务”","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4568","BK4139","BK4585","BK4588","NVAX"],"gpt_icon":0},{"id":"2582348679","title":"B. Riley下调诺瓦瓦克斯医药目标价至16美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2582348679","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582348679?lang=zh_cn&edition=full","pubTime":"2025-11-12 11:24","pubTimestamp":1762917849,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4585","BK4568","BK4547","BK4139","BK4588","NVAX"],"gpt_icon":0},{"id":"1169223015","title":"诺瓦瓦克斯医药高管表示，预计2026-27赛季Nuvaxovid的版税将显著增长，与2025年相比","url":"https://stock-news.laohu8.com/highlight/detail?id=1169223015","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169223015?lang=zh_cn&edition=full","pubTime":"2025-11-06 22:06","pubTimestamp":1762437990,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药高管表示，预计2026-27赛季Nuvaxovid的版税将显著增长，与2025年相比","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVAX","BK4547","BK4568","BK4139","BK4585","BK4588"],"gpt_icon":0},{"id":"1159594138","title":"异动解读 | 诺瓦瓦克斯医药盘前大涨5.85%，季度收入超出预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1159594138","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159594138?lang=zh_cn&edition=full","pubTime":"2025-11-06 21:06","pubTimestamp":1762434403,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药（Novavax，股票代码：NVAX）今日盘前大涨5.85%，引起投资者关注。这一显著涨幅主要源于公司公布的第三季度财报超出市场预期。\n\n根据最新公布的财务报告，诺瓦瓦克斯第三季度总营收达到7040万美元，远超分析师平均预期的4213万美元。公司表示，这一亮眼业绩主要得益于与新冠疫苗合作相关的里程碑付款。\n\n作为一家生物技术公司，诺瓦瓦克斯此次超出预期的财务表现显示了其在新冠疫苗领域的持续影响力。这一业绩不仅反映了公司当前的经营状况，还可能预示着其未来在疫苗研发和商业化方面的潜力。投资者对这一积极信号做出了正面反应，推动了股价的大幅上涨。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVAX"],"gpt_icon":0},{"id":"1109168706","title":"诺瓦瓦克斯医药完成Nuvaxovid™在美国的市场授权转让给赛诺菲，触发2500万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1109168706","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109168706?lang=zh_cn&edition=full","pubTime":"2025-11-04 20:00","pubTimestamp":1762257635,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药完成Nuvaxovid™在美国的市场授权转让给赛诺菲，触发2500万美元里程碑付款","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","NVAX","BK4588","BK4139","BK4547","BK4568"],"gpt_icon":0},{"id":"1134584006","title":"诺瓦瓦克斯医药：设施租约转让及某些相关资产出售将使公司获得4000万美元付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1134584006","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134584006?lang=zh_cn&edition=full","pubTime":"2025-10-22 19:03","pubTimestamp":1761130981,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药：设施租约转让及某些相关资产出售将使公司获得4000万美元付款","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4568","BK4547","BK4585","NVAX","BK4588"],"gpt_icon":0},{"id":"1171424111","title":"诺瓦瓦克斯医药实施计划中的场地整合，进一步降低成本支出以符合公司战略","url":"https://stock-news.laohu8.com/highlight/detail?id=1171424111","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171424111?lang=zh_cn&edition=full","pubTime":"2025-10-22 19:01","pubTimestamp":1761130871,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药实施计划中的场地整合，进一步降低成本支出以符合公司战略","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4547","BK4568","NVAX","BK4139"],"gpt_icon":0},{"id":"1148453092","title":"诺瓦瓦克斯医药有资格就Sanofi利用其Matrix-M佐剂开发的前四款产品获得2亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1148453092","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148453092?lang=zh_cn&edition=full","pubTime":"2025-10-07 19:04","pubTimestamp":1759835076,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药有资格就Sanofi利用其Matrix-M佐剂开发的前四款产品获得2亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVAX","BK4139","BK4547","BK4568","BK4588","BK4585"],"gpt_icon":0},{"id":"1170856282","title":"诺瓦瓦克斯医药：与Sanofi合作开发的组合产品（含新冠疫苗）有望获得高达3.5亿美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1170856282","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170856282?lang=zh_cn&edition=full","pubTime":"2025-10-07 19:03","pubTimestamp":1759835001,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药宣布，其与Sanofi共同开发的组合产品（包括该公司的新冠疫苗）符合条件，未来有望获得高达3.5亿美元的里程碑付款。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4568","BK4588","BK4585","NVAX","BK4547"],"gpt_icon":0},{"id":"1153358132","title":"诺瓦瓦克斯医药完成向Sanofi转让其新冠疫苗Nuvaxovid在欧盟的营销授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1153358132","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153358132?lang=zh_cn&edition=full","pubTime":"2025-10-07 19:02","pubTimestamp":1759834963,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药完成向Sanofi转让其新冠疫苗Nuvaxovid在欧盟的营销授权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVAX","BK4588","BK4547","BK4585","BK4568","BK4139"],"gpt_icon":0},{"id":"1168376498","title":"诺瓦瓦克斯医药持续推进与Sanofi合作，完成Nuvaxovid®欧盟市场授权转移并获得2500万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1168376498","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168376498?lang=zh_cn&edition=full","pubTime":"2025-10-07 19:01","pubTimestamp":1759834905,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药持续推进与Sanofi的合作伙伴关系，成功完成Nuvaxovid®在欧盟的市场授权转移，并因此获得2500万美元的里程碑付款。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","NVAX","BK4568","BK4585","BK4139","BK4588"],"gpt_icon":0},{"id":"2567190639","title":"生物科技股集体重挫！报道称特朗普政府将儿童死亡甩锅新冠疫苗接种","url":"https://stock-news.laohu8.com/highlight/detail?id=2567190639","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567190639?lang=zh_cn&edition=full","pubTime":"2025-09-13 06:38","pubTimestamp":1757716705,"startTime":"0","endTime":"0","summary":"研发新冠疫苗的BioNTech盘中跌超10%、莫德纳跌超7%、Novavax跌超4%。投资者担心，如果特朗普政府进一步收紧疫苗接种政策，可能对疫苗制造商的业务造成重大冲击，特别是对莫德纳这类高度依赖新冠疫苗收入的公司。更新中","market":"us","thumbnail":"https://static.tigerbbs.com/632b4e916ff966270173f4303843021f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/632b4e916ff966270173f4303843021f"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3755508","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"ae8bc75ba4d1918dcafc0476d86c6d53","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3755508","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"生物科技股集体重挫！报道称特朗普政府将儿童死亡甩锅新冠疫苗接种","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["STRO","KALV","TARS","AZN","MRK","NVAX","BMY","ABUS","PFE","NVS","PGEN","ARCT","BNTX","BK4009","TRVI","MRNA","PSNL","TVTX","SRPT"],"gpt_icon":1},{"id":"2562872654","title":"美国卫生部长小肯尼迪：针对新冠疫苗的紧急使用授权现已被撤销。美国食品药品监督管理局（FDA）现已向高风险人群授予疫苗上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2562872654","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562872654?lang=zh_cn&edition=full","pubTime":"2025-08-28 00:42","pubTimestamp":1756312963,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8431827f5b4d4e6f6bf8f5bba1300d3c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4532","BK4551","LU0306807586.USD","LU1066053197.SGD","LU0225771236.USD","159646","BK4550","LU0225284248.USD","PFE","BK4592","SG9999013999.USD","BK4599","BK4534","BK4547","LU0456855351.SGD","SG9999001176.SGD","MRNA","BK4139","LU1066051498.USD","LU0868494617.USD","BK4007","IE00BLSP4239.USD","BK4588","BK4533","LU0122379950.USD","SG9999001176.USD","SG9999003800.SGD","LU0306806265.USD","SG9999002224.SGD","BK4568","SG9999002232.USD","LU0170899867.USD","IE00BLSP4452.SGD","IE0002270589.USD","LU0234572021.USD","LU0321505439.SGD","SG9999011175.SGD","IE00BBT3K403.USD","BK4585","LU0058720904.USD","LU0985481810.HKD","LU1057294990.SGD","SGXZ57979304.SGD","LU0321505868.SGD","BK4501","NVAX","LU1023059063.AUD","LU1894683264.USD","IE00B19Z3581.USD","LU1894683348.USD"],"gpt_icon":0},{"id":"2562275651","title":"美股生物医药股全线下跌！特朗普再放狠话：下调药品价格1400%至1500%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562275651","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562275651?lang=zh_cn&edition=full","pubTime":"2025-08-26 06:20","pubTimestamp":1756160400,"startTime":"0","endTime":"0","summary":"8月26日，美国总统特朗普周一表示，其政府将大幅下调药品价格，幅度高达1400%至1500%，并重申对医药价格的强硬立场，同时计划对进口药品加征更高关税。这一表态是在特朗普向多家制药巨头发出正式信函近一个月后作出的。特朗普称此举旨在推动制药产业回流美国。今年7月，特朗普曾威胁对进口药征收200%关税，但随后下调了提议。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c5d4bd894299c7bf3aa4d01ffdbe4f66","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334980.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"医药股全线下跌！特朗普再放狠话：下调药品价格1400%至1500%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SRPT","BNTX","MRK","LLY","PFE","SNY","MRNA","NVAX"],"gpt_icon":1},{"id":"2561140555","title":"美国生物科技股上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2561140555","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561140555?lang=zh_cn&edition=full","pubTime":"2025-08-22 23:08","pubTimestamp":1755875329,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4585","BK4568","BK4547","BK4139","BK4533","BK4548","BK4532","BK4551","MRNA","BK4501","BK4534","BK4588","NVAX"],"gpt_icon":0},{"id":"1119825151","title":"异动解读 | 诺瓦瓦克斯医药盘中大跌10.05%，可转债再融资和评级下调双重利空","url":"https://stock-news.laohu8.com/highlight/detail?id=1119825151","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119825151?lang=zh_cn&edition=full","pubTime":"2025-08-21 21:37","pubTimestamp":1755783459,"startTime":"0","endTime":"0","summary":"周四盘中，疫苗制造商诺瓦瓦克斯医药股价大幅下跌10.05%，引发市场广泛关注。此次股价暴跌主要受两大利空因素影响：公司宣布的可转债再融资计划以及美国银行的评级下调。据悉，诺瓦瓦克斯医药计划发行2.25亿美元2031年到期的4.625%可转换债券。与此同时，美国银行对诺瓦瓦克斯医药的评级进行了下调，从\"中性\"调整为\"跑输大市\"，并将目标价从9美元下调至7美元。这无疑给诺瓦瓦克斯医药的股价带来了进一步的下行压力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVAX"],"gpt_icon":1},{"id":"1167073113","title":"异动解读 | 诺瓦瓦克斯医药遭美银下调评级，盘前大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=1167073113","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167073113?lang=zh_cn&edition=full","pubTime":"2025-08-21 19:54","pubTimestamp":1755777275,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药（NVAX）今日盘前大跌5.03%，引发市场关注。\n\n消息面上，美国银行对诺瓦瓦克斯医药的评级和目标价进行了下调。美银将诺瓦瓦克斯医药的评级从\"中性\"下调至\"跑输大市\"，同时将目标价从9美元下调至7美元。这一评级调整显然对投资者信心造成了打击，导致股价在盘前交易中大幅下挫。\n\n美银此次下调评级和目标价可能反映了对诺瓦瓦克斯医药未来业务前景的担忧。作为一家生物技术公司，诺瓦瓦克斯医药的股价往往对市场情绪和分析师评级变化较为敏感。此次评级下调可能会引发更多投资者重新评估该公司的投资价值，短期内可能会给股价带来进一步压力。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVAX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novavax.com","stockEarnings":[{"period":"1week","weight":-0.0129},{"period":"1month","weight":-0.0866},{"period":"3month","weight":-0.1316},{"period":"6month","weight":-0.0792},{"period":"1year","weight":-0.1735},{"period":"ytd","weight":-0.1468}],"compareEarnings":[{"period":"1week","weight":0.0069},{"period":"1month","weight":0.0136},{"period":"3month","weight":0.0574},{"period":"6month","weight":0.1423},{"period":"1year","weight":0.1263},{"period":"ytd","weight":0.1677}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novavax, Inc.于1987年根据美国特拉华州法律注册成立，是一家临床阶段的生物制药公司，专注于重组纳米颗粒疫苗和佐剂的发现、开发和商业化。该公司的疫苗技术平台基于包括病毒样颗粒（VLP）和蛋白质纳米颗粒候选疫苗的专有重组纳米颗粒疫苗技术。该公司的候选疫苗是基因工程的三维纳米结构，其中包含了免疫学上重要的蛋白质。公司的疫苗产品管线针对多种传染病，候选药物目前处于呼吸道合胞病毒（RSV）、季节性流感、大流行性流感的临床开发阶段。此外，该公司在印度的合资公司CPL Biologics Private Limited（CPLB）正在积极开发多款候选疫苗，这些候选疫苗由诺瓦瓦克斯医药进行基因工程改造。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.101177},{"month":2,"riseRate":0.566667,"avgChangeRate":0.039349},{"month":3,"riseRate":0.266667,"avgChangeRate":-0.040904},{"month":4,"riseRate":0.466667,"avgChangeRate":0.00903},{"month":5,"riseRate":0.533333,"avgChangeRate":0.126007},{"month":6,"riseRate":0.5,"avgChangeRate":0.090368},{"month":7,"riseRate":0.566667,"avgChangeRate":0.019422},{"month":8,"riseRate":0.533333,"avgChangeRate":0.039885},{"month":9,"riseRate":0.5,"avgChangeRate":-0.036425},{"month":10,"riseRate":0.3,"avgChangeRate":0.027361},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.003351},{"month":12,"riseRate":0.366667,"avgChangeRate":-0.037947}],"exchange":"NASDAQ","name":"诺瓦瓦克斯医药","nameEN":"Novavax"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺瓦瓦克斯医药(NVAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺瓦瓦克斯医药(NVAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺瓦瓦克斯医药,NVAX,诺瓦瓦克斯医药股票,诺瓦瓦克斯医药股票老虎,诺瓦瓦克斯医药股票老虎国际,诺瓦瓦克斯医药行情,诺瓦瓦克斯医药股票行情,诺瓦瓦克斯医药股价,诺瓦瓦克斯医药股市,诺瓦瓦克斯医药股票价格,诺瓦瓦克斯医药股票交易,诺瓦瓦克斯医药股票购买,诺瓦瓦克斯医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺瓦瓦克斯医药(NVAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺瓦瓦克斯医药(NVAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}